Type I IFNs, IFN-α and IFN-β, are early effectors of innate immune responses against microbes that can also regulate subsequent adaptive immunity by promoting antimicrobial Th1-type responses. In contrast, the ability of IFN-β to inhibit autoimmune Th1 responses is thought to account for some of the beneficial effects of IFN-β therapy in the treatment of relapsing remitting multiple sclerosis. To understand the basis of the paradoxical effects of IFN-β on the expression of Th1-type immune responses, we developed an in vitro model of monocyte-derived dendritic cell (DC)-dependent, human naive Th cell differentiation, in which one can observe both positive and negative effects of IFN-β on the generation of Th1 cells. In this model we found that the timing of IFN-β exposure determines whether IFN-β will have a positive or a negative effect on naive Th cell differentiation into Th1 cells. Specifically, the presence of IFN-β during TNF-α-induced DC maturation strongly augments the capacity of DC to promote the generation of IFN-γ-secreting Th1 cells. In contrast, exposure to IFN-β during mature DC-mediated primary stimulation of naive Th cells has the opposite effect, in that it inhibits Th1 cell polarization and promotes the generation of an IL-10-secreting T cell subset. Studies with blocking mAbs and recombinant cytokines indicate that the mechanism by which IFN-β mediates these contrasting effects on Th1 cell generation is at least in part by differentially regulating DC expression of IL-12 family cytokines (IL-12 and/or IL-23, and IL-27) and IL-18.